Analysts See Opportunity in Jazz (JAZZ) Sell-Off

May 8, 2013 12:03 PM

Cantor Fitzgerald today maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a price target of $86.00. Shares of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found